Related Experiment Video

Updated: Jul 9, 2026

Comparative Strategies for Ubiquitination Detection in Mammalian Cell Lysates Using SMAD2/SMURF2 as a Model
09:00

Comparative Strategies for Ubiquitination Detection in Mammalian Cell Lysates Using SMAD2/SMURF2 as a Model

Published on: April 17, 2026

Patented small molecule inhibitors in the ubiquitin proteasome system

Philippe Guédat1, Frédéric Colland

  • 1Hybrigenics SA, 3-5 Impasse Reille, 75014 Paris, France. pguedat@hybrigenics.com

BMC Biochemistry
|December 6, 2007
PubMed

Insights

The ubiquitin proteasome system (UPS) is crucial in diseases like cancer. New patented inhibitors targeting UPS components offer novel therapeutic strategies for various human conditions.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • The ubiquitin proteasome system (UPS) plays a critical role in cellular protein homeostasis.
  • UPS dysregulation is linked to the development of numerous human diseases, including cancers and neurodegenerative disorders.
  • The success of bortezomib (Velcade®) validates the UPS as a therapeutic target, particularly in oncology.

Purpose of the Study:

  • To review recently patented proteasome inhibitors.
  • To highlight novel small molecule inhibitors targeting specific UPS components, such as E3 ubiquitin ligases and deubiquitylating enzymes.

Main Methods:

  • Literature review of patented proteasome inhibitors.
  • Analysis of small molecule inhibitors targeting specific UPS enzymes.
  • Information sourced from the Targeted Proteins database (TPdb).

Main Results:

  • Identification of new patented proteasome inhibitors.
  • Characterization of patented small molecule inhibitors with specificity for E3 ubiquitin ligases and deubiquitylating enzymes.
  • The review consolidates recent advancements in UPS-targeted drug development.

Conclusions:

  • The UPS remains a significant target for therapeutic intervention in human diseases.
  • Patented inhibitors targeting specific UPS components represent promising avenues for future drug discovery.
  • Continued research into UPS modulation holds potential for treating cancer and neurodegenerative conditions.

More Related Videos

Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology10:25

Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology

Published on: November 22, 2024

Using Phage Display to Develop Ubiquitin Variant Modulators for E3 Ligases06:30

Using Phage Display to Develop Ubiquitin Variant Modulators for E3 Ligases

Published on: August 27, 2021

Related Concept Videos

The Proteasome01:13

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
The Proteasome02:18

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
The Proteasome02:18

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
Regulated Protein Degradation02:58

Regulated Protein Degradation

It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Regulated Protein Degradation02:58

Regulated Protein Degradation

It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
The Proteasome Structure01:17

The Proteasome Structure

The ubiquitin-proteasome pathway is a well-known mechanism utilized by eukaryotic cells to remove cytoplasmic proteins that are misfolded, damaged, or no longer needed. In this pathway, the protein that needs to be eliminated undergoes a process called ubiquitination, where a chain of ubiquitin molecules is attached to the 48th lysine residue of the target protein. This ubiquitin modification helps the proteasome distinguish between a target protein and a healthy protein.
The proteasome is an...